LPTX - Leap Therapeutics rallies on fast track status for DKN-01

USFDA granted Leap Therapeutics (LPTX) +8.8% fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express high Dickkopf-1 protein (DKK1), following disease progression on or after prior fluoropyrimidine- and platinum- containing chemotherapy and if appropriate, human epidermal receptor growth factor (HER2)/neu-targeted therapy.DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of DKK1 protein, a modulator of Wnt/Beta-catenin signaling.

For further details see:

Leap Therapeutics rallies on fast track status for DKN-01